United Therapeutics (UTHR) Misses Q2 EPS by 94c
Tweet
Share
E-mail
Get Alerts UTHR Hot Sheet
Price: $512.70 +0.45%
Revenue Growth %: -1.2%
Financial Fact:
Research and development: 45.9M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Revenue Growth %: -1.2%
Financial Fact:
Research and development: 45.9M
Today's EPS Names:
PMCB, PLCE, DOMO, More
Join SI Premium – FREE
United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $6.41, $0.94 worse than the analyst estimate of $7.35. Revenue for the quarter came in at $798.6 million versus the consensus estimate of $804.98 million.
For earnings history and earnings-related data on United Therapeutics (UTHR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- NIO Inc. (NIO) Tops Q2 EPS by 33c; offers guidance
- Raytheon wins $42.5M Navy air traffic contract
- Credo Technology Group Holding (CRDO) Tops Q1 EPS by 4c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
